Pulmongene Announces FDA Clearance to initiate 52-Week Phase IIb Global MRCT for PMG 1015, a First-in-Class Therapeutic Antibody for IPF
[Beijing, China] – January 19th, 2026. Pulmongene Ltd., […]
Pulmongene announces to present PMG1015 Phase 1b Clinical Trial Results as a Late-Breaking Abstract at European Respiratory Society Congress (ERS) 2025
Beijing, China – September 2, 2025 – Pulmongene Ltd., a
Pulmongene Announces First Patient Dosed in Phase 1b Clinical Trial Evaluating PMG1015 in Idiopathic Pulmonary Fibrosis Patients
On July 5, 2023, Pulmongene Ltd. announced that its inv